With U.S. stock futures trading mixed this morning on Thursday, some of the stocks that may grab investor focus today are as follows:Wall Street expects PepsiCo Inc. (NASDAQ:PEP) to post quarterly earnings at $2.26 per share on revenue of $23.83 billion before the opening bell, according to data from Benzinga Pro. PepsiCo shares rose 0.1% to $139.00 in after-hours trading.Costco Wholesale Corp. (NASDAQ:COST) reported net sales of $26.58 billion for the retail month of September, which includes the five week ...

Core Points - The announcement contains information classified as inside information under the Market Abuse Regulation (EU) No. 596/2014, which is part of UK domestic law following the European Union (Withdrawal) Act 2018 [1]

Core Insights - Zelluna has received positive feedback from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regarding its ZI-MA4-1 program, which is a significant step towards clinical trials [1][3] - The company is preparing for its first-in-human trial of ZI-MA4-1, with The Christie in Manchester as the lead site and Professor Fiona Thistlethwaite as the proposed Chief Investigator [2][6] - The planned Phase I trial will be an open-label, dose-escalation study focusing on the safety, tolerability, and preliminary efficacy of ZI-MA4-1 across multiple solid tumors, with initial data expected in 2026 [3][5] Company Overview - Zelluna Immunotherapy specializes in developing allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cells for cancer treatment, aiming to overcome limitations of current therapies, especially for solid tumors [5] - The company's lead program, ZI-MA4-1, targets the MAGE-A4 tumor antigen and is anticipated to enter clinical trials in 2026 [5][6] - Zelluna's proprietary manufacturing process allows for scalable and cost-effective production of TCR-NK cell therapies, enhancing patient accessibility [5]

Company Overview - Turn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation dermatology, wound care, and anti-infective therapies [5] - The company is based in California and recently commenced trading on the Nasdaq Capital Market [2] Market Performance - Turn Therapeutics' shares surged by 134.29% after the market closed on Wednesday, reaching a closing price of $16.40 [1] - During regular trading on the same day, TTRX shares fell by 26.47%, closing at $7.00 [5] Nasdaq Listing - The Securities and Exchange Commission (SEC) declared Turn's registration statement on Form S-1 effective on September 30 [2] - The Nasdaq Exchange welcomed Turn Therapeutics on social media, highlighting its innovative approach in pharmaceutical technologies [2] Leadership Insights - Bradley Burnham, the founder and CEO, emphasized the company's lean operating model, stating it was "built on a shoestring, with an absolute disdain for waste" [3] Closing Bell Ceremony - Turn Therapeutics participated in the closing bell ceremony at Nasdaq's MarketSite in New York, which was broadcast live [4]

Core Insights - U.S.-listed biotech and healthcare stocks experienced significant bullish activity in after-hours trading, with Turn Therapeutics Inc. leading the surge with a 134.29% increase to $16.40 following its Nasdaq debut [1] Group 1: Company Performances - Talphera Inc. reached a new 52-week high in regular trading and added 4.55% after hours to close at $1.38, driven by momentum despite no new updates [2] - Personalis Inc. rose 1.50% to $8.81 in after-hours trading, having hit a 52-week high earlier in the day, likely due to ongoing investor interest in precision oncology [2] - Ionis Pharmaceuticals Inc. climbed 3.64% to $72.51 after hours, supported by its Innovation Day presentation and reaffirmation of its pipeline strategy, leading to a new 52-week high during regular trading [3] - Sensei Biotherapeutics Inc. increased 5.23% to $12.08, with anticipation building ahead of its pipeline updates scheduled for October 20 [3] - Corbus Pharmaceuticals Holdings Inc. gained 4.77% to $14.06, preparing for participation in the Piper Sandler Virtual Oncology Symposium on October 9 [4] - Longeveron Inc. advanced 5.71% to $0.9801, with expectations for insights into its regenerative medicine pipeline at the ROTH Healthcare Opportunities Conference [4] - Palisade Bio Inc. rose 5.00% to $2.10 in after-hours trading, buoyed by a recent $138 million public offering that strengthened its balance sheet ahead of Phase 2 trials [5] Group 2: Market Trends - The after-hours session showcased a mix of technical breakouts, event-driven anticipation, and momentum trading, indicating a fertile environment for volatility and investment opportunities in the biotech sector [6]

Core Viewpoint - Apogee Therapeutics, Inc. has announced a public offering of 6,951,221 shares of common stock priced at $41.00 per share, aiming to raise approximately $300 million before expenses [1]. Group 1: Offering Details - The offering includes pre-funded warrants for certain investors to purchase up to 365,853 shares at a price of $40.99999 per warrant, with an exercise price of $0.00001 per share [1]. - The offering is expected to close on October 10, 2025, subject to customary closing conditions [1]. - Underwriters have an option to purchase an additional 1,097,561 shares at the public offering price within 30 days [1]. Group 2: Underwriters - Jefferies, BofA Securities, Guggenheim Securities, and TD Cowen are acting as joint book-running managers for the offering, while BTIG serves as a passive bookrunner [2]. Group 3: Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology markets, including treatments for Atopic Dermatitis, asthma, Eosinophilic Esophagitis, and Chronic Obstructive Pulmonary Disease [5]. - The company's lead program, APG777, targets Atopic Dermatitis, which is noted as a large and under-penetrated market [5]. - Apogee aims to achieve best-in-class profiles through its antibody programs by addressing limitations of existing therapies and optimizing properties such as half-life [5].

Core Insights - The article discusses the potential for accelerated approval of Dyne Therapeutics' product DYNE-101, which may be achievable through the use of surrogate biomarkers [2]. Company Overview - Dyne Therapeutics is highlighted as a company under analysis, with a focus on its innovative approaches in the biotech sector [2]. Investment Analysis - The author provides a comprehensive analysis of various pharmaceutical companies, including a model portfolio of over 10 small and mid-cap stocks, aimed at assisting healthcare investors in making informed decisions [2].

Core Viewpoint - Apogee Therapeutics, Inc. has initiated an underwritten public offering of its common stock and pre-funded warrants, with the intention to utilize the proceeds for various research and development activities, including clinical trials and manufacturing [1][2]. Group 1: Offering Details - The public offering includes a 30-day option for underwriters to purchase an additional 15% of shares at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund preclinical studies, clinical trials, manufacturing, and commercial readiness activities for the company's antibody programs [2]. - Additional uses include research and development activities, capital expenditures, working capital, and general corporate purposes [2]. Group 3: Company Overview - Apogee Therapeutics is focused on developing novel biologics for inflammatory and immunology markets, targeting conditions such as Atopic Dermatitis, asthma, and Chronic Obstructive Pulmonary Disease [6]. - The company's lead program, APG777, is aimed at treating Atopic Dermatitis, which is identified as a significant and under-penetrated market [6]. - Apogee's antibody programs are designed to enhance existing therapies by targeting established mechanisms and optimizing properties through advanced engineering [6].

Core Insights - Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is experiencing a significant surge without any specific news to justify the movement [1] - The company reported second-quarter revenue of $19.22 million, exceeding analyst estimates of $16.23 million, but reported a loss of 41 cents per share, which was worse than the expected loss of 34 cents per share [1] - The stock price increased by 17.21% to $6.12 during the publication time, reflecting strong investor interest in the company's innovative approaches [9] Financial Performance - Recursion's second-quarter revenue was $19.22 million, surpassing analyst expectations of $16.23 million [1] - The reported loss for the second quarter was 41 cents per share, which missed the analyst estimate of a loss of 34 cents per share [1] Strategic Developments - In June, the company streamlined its operating strategy and announced a workforce reduction of approximately 20%, extending its cash runway into the fourth quarter of 2027 [2] - The company is developing REC-3565, a MALT1 inhibitor designed to interfere with the growth of blood cancer cells, currently in Phase 1 trials [4][5] Market Context - Recursion Pharmaceuticals operates in the highly competitive biotechnology sector, with a market capitalization of $2.68 billion [9] - The stock has shown considerable volatility, with a 52-week range of $3.79 to $12.36, indicating fluctuating market sentiment influenced by advancements in drug discovery technologies [10]

Core Thesis - Nuvation Bio Inc. (NUVB) is positioned as a high-risk, high-reward oncology biotech with a focus on next-generation kinase inhibitors targeting genetically defined cancers, supported by a strong management team and promising early commercial adoption of its lead product, Taletrectinib [1][2][4]. Company Overview - Nuvation Bio was founded in 2018 by Dr. David T. Hung and specializes in oncology, particularly in developing kinase inhibitors [2]. - The company has a highly qualified leadership team, with 70-80% of staff holding MD or PhD degrees and extensive pharmaceutical development experience [2]. Financial Position - Nuvation Bio is well-capitalized, with sufficient cash reserves to fund operations for 2-3 years without dilution, maintaining a historical burn rate of $40-50 million per quarter [3]. - The company's share price was trading at $3.22 as of September 23rd [1]. Product Pipeline - The company's pipeline is anchored by Taletrectinib (IBTROZI), an oral ROS1 tyrosine kinase inhibitor that received FDA approval in June 2025 for non-small cell lung cancer (NSCLC) and is designated as a "Preferred Option" by the NCCN [4]. - Early commercial adoption of Taletrectinib exceeded expectations, generating $4.8 million in GAAP revenue in August, surpassing analyst estimates [4]. Market Potential - Long-term data for Taletrectinib indicates improved progression-free survival and manageable side effects, with the potential to capture a market valued at approximately $6 billion [4]. - Conservative revenue modeling for Q3 estimates IBTROZI sales between $1.15 million and $3.83 million, which is below analyst projections [5]. Competitive Landscape - Nuvation Bio is actively pursuing head-to-head trials against competitors like Vorasidenib, which could enhance its market position [4]. - Key risks include commercialization execution, competition, and pipeline uncertainty, but these are mitigated by management's experience and ongoing FDA discussions [5]. Investment Outlook - Given the early adoption of Taletrectinib, strong clinical data, and management competence, Nuvation Bio presents a fair value estimate ranging from $5 to $10, with significant upside potential if adoption and trials succeed [5].